Cancer targets and uses thereof
US-2016340425-A1 · Nov 24, 2016 · US
Interferon alpha and omega antibody antagonists
US10155809B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10155809-B2 |
| Application number | US-201715707317-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 18, 2017 |
| Priority date | Mar 15, 2013 |
| Publication date | Dec 18, 2018 |
| Grant date | Dec 18, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Broadly neutralizing interferon-α and interferon-ω antibody antagonists, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of diseases associated with increased production of IFNα and IFNω.
First claim
Opening claim text (preview).
We claim: 1. A method of treating systemic lupus erythematosus (SLE) in a patient by inhibiting IFNα and IFNω in the patient, comprising administering to the patient a therapeutically effective amount of an isolated antibody comprising (i) a heavy chain variable region (VH) amino acid sequence of SEQ ID NO:23 and a light chain variable region (VL) of amino acid sequence of SEQ ID NO:24 or (ii) a VH amino acid sequence of SEQ ID NO:27 and a VL amino acid sequence of SEQ ID NO:28. 2. The method of claim 1 , wherein the patient exhibits a Type I interferon signature. 3. The method of claim 1 , wherein the antibody is a bispecific antibody. 4. The method of claim 3 , wherein the bispecific antibody binds BLyS, CD40L, IL-6, CD27, BDCA2 or the p40 subunit of IL-12 or IL-23.
Assignees
Inventors
Classifications
for hyperglycaemia, e.g. antidiabetics · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Immunomodulators · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Drugs for disorders of the nervous system · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10155809B2 cover?
- Broadly neutralizing interferon-α and interferon-ω antibody antagonists, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of diseases associated with increased production of IFNα and IFNω.
- Who is the assignee on this patent?
- Janssen Biotech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/249. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).